PT  - JOURNAL ARTICLE
AU  - Susan F. Steinberg
TI  - Regulation of Protein Kinase D1 Activity
AID  - 10.1124/mol.111.075986
DP  - 2011 Dec 21
TA  - Molecular Pharmacology
PG  - mol.111.075986
4099  - http://molpharm.aspetjournals.org/content/early/2011/12/21/mol.111.075986.short
4100  - http://molpharm.aspetjournals.org/content/early/2011/12/21/mol.111.075986.full
AB  - Protein kinase D1 (PKD1) is a stress-activated serine/threonine kinase that plays a vital role in various physiologically important biological processes, including cell growth, apoptosis, adhesion, motility, and angiogenesis. Dysregulated PKD1 expression also contributes to the pathogenesis of certain cancers and cardiovascular disorders. Studies to date have focused primarily on the canonical membrane-delimited pathway for PKD1 activation by G protein-coupled receptors or peptide growth factors. Here, agonist-dependent increases in diacylglycerol accumulation lead to the activation of protein kinase C (PKC) and PKC-dependent phosphorylation of PKD1 at two highly conserved serine residues in the activation loop; this modification increases PKD1's catalytic activity, as assessed by PKD1 autophosphorylation at a consensus phosphorylation motif at the extreme C-terminus. However, recent studies expose additional controls and consequences for PKD1 activation loop and C-terminal phosphorylation as well as additional autophosphorylation reactions and trans-phosphorylations (by PKC and other cellular enzymes) that contribute to the spatiotemporal control of PKD1 signaling in cells. This review focuses on the multi-site phosphorylations that are known or predicted to influence PKD1's catalytic activity and also may influence docking interactions with cellular scaffolds and trafficking to signaling microdomains in various subcellular compartments. These modifications represent novel targets for the development of PKD1-directed pharmaceuticals for the treatment of cancers and cardiovascular disorders.